Ferenci P
University Clinic of Internal Medicine IV, Vienna, Austria.
Int J Clin Pract. 2003 Sep;57(7):610-5.
Compared with conventional interferon alfa, peginterferon alfa-2a (40KD) has improved pharmacokinetics, provides sustained therapeutic plasma levels, and can be administered once weekly. In randomised, multinational trials, peginterferon alfa-2a (40KD) 180 microg once weekly was significantly more effective than three times weekly interferon alfa-2a in patients with chronic hepatitis C, including patients with cirrhosis. Peginterferon alfa-2a (40KD) and ribavirin 1000/1200 mg/day for 48 weeks produced significantly higher sustained responses than three times weekly interferon alfa-2b and ribavirin 1000/1200 mg/day in patients with chronic hepatitis C including those with HCV genotype 1, genotypes 2/3 and those with high or low viral loads at baseline. The drug is well tolerated when given alone or in combination with ribavirin. Health-related quality of life was significantly less impaired during treatment with peginterferon alfa-2a (40KD) than interferon alfa-2a in randomised trials. Peginterferon alfa-2a (40KD) is widely approved for use in patients with chronic hepatitis C.
与传统干扰素α相比，聚乙二醇干扰素α-2a（40KD）具有改善的药代动力学，能提供持续的治疗性血浆水平，且可每周给药一次。在随机、多国试验中，对于慢性丙型肝炎患者（包括肝硬化患者），聚乙二醇干扰素α-2a（40KD）每周一次180微克显著比每周三次的干扰素α-2a更有效。对于慢性丙型肝炎患者（包括丙型肝炎病毒基因1型、基因2/3型以及基线病毒载量高或低的患者），聚乙二醇干扰素α-2a（40KD）和利巴韦林1000/1200毫克/天治疗48周产生的持续应答显著高于每周三次的干扰素α-2b和利巴韦林1000/1200毫克/天。该药物单独使用或与利巴韦林联合使用时耐受性良好。在随机试验中，与干扰素α-2a相比，聚乙二醇干扰素α-2a（40KD）治疗期间对健康相关生活质量的损害显著更小。聚乙二醇干扰素α-2a（40KD）已被广泛批准用于慢性丙型肝炎患者。
